Protein Design Labs Inc. decided against further development of Zamyl as an acute myeloid leukemia treatment on news that its Phase III trial failed to show statistical significance. The results were ...
SAN FRANCISCO (MarketWatch) -- PDL BioPharma Inc. after Tuesday's closing bell said Roche will discontinue its agreement with PDL to jointly develop daclizumab for organ transplant patients on ...
Roche has decided to drop its role as a collaborator in the development of PDL Biopharma's daclizumab in asthma following a portfolio review. It will continue to collaborate, though, on daclizumab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results